Mga Batayang Estadistika
| LEI | 549300X04FB2QPCJ5J24 |
| CIK | 1308547 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dolby Laboratories, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 27, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| July 31, 2025 |
Dolby Laboratories Reports Third Quarter 2025 Financial Results EX-99.1 Exhibit 99.1 Dolby Laboratories Reports Third Quarter 2025 Financial Results SAN FRANCISCO, July 31, 2025 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the third quarter of fiscal 2025. “We had solid results in Q3 and we continue to see strong engagement with creators, distributors and device manufacturers,” said Kevin Yeaman, President and CEO, |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal exec |
|
| May 29, 2025 |
Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2024 Exhibit 1.01 GLOSSARY OF TERMS The following table summarizes certain terms and abbreviations that may be used within the text of this report: Abbreviation Term CMRT RMI’s Conflict Minerals Reporting Template Communication Suspended - Not Interested RMI assigned smelter or refiner status for a facility which has strongly communicated a lack of interest in participation in the RMI RMAP program Conf |
|
| May 1, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 1, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| May 1, 2025 |
Dolby Laboratories Reports Second Quarter 2025 Financial Results Exhibit 99.1 Dolby Laboratories Reports Second Quarter 2025 Financial Results SAN FRANCISCO, May 1, 2025 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the second quarter of fiscal 2025. “We had a strong second quarter with continued momentum across our end markets, especially in Auto and Mobile,” said Kevin Yeaman, President and CEO, Dolby Laboratories. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 7, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOLBY LABORATORIES, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Dolby Laboratories, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Dolby Laboratories, Inc. T |
|
| January 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 27, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| January 29, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| January 29, 2025 |
Dolby Laboratories Reports First Quarter 2025 Financial Results Exhibit 99.1 Dolby Laboratories Reports First Quarter 2025 Financial Results SAN FRANCISCO, January 29, 2025 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the first quarter of fiscal 2025. “We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “In Q1, Dolby Atmos and Dolby Vision momentum continued across devic |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| December 20, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| December 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| November 19, 2024 |
Dolby Laboratories, Inc. Amended and Restated Policy on Recoupment of Compensation DOLBY LABORATORIES, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION As Amended and Restated effective August 1, 2023 Dolby Laboratories, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Compensation Committee (the “Compensation Committee”) of Company’s Board of Directors (the “Board”), having previously adopted a Policy on Recoupment of Incentiv |
|
| November 19, 2024 |
Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2024 Financial Results Exhibit 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2024 Financial Results SAN FRANCISCO, November 19, 2024 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the fourth quarter and fiscal year 2024. “We are pleased with the progress we made in fiscal 2024,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “As we enter fiscal 2025, |
|
| November 19, 2024 |
Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of November 14, 2024 among DOLBY LABORATORIES, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, and BANK OF AMERICA, N.A., as the Lender TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms 1 1.02 Other Interpretive Provisions 23 1.03 Accounting Terms 24 1.04 |
|
| November 19, 2024 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 27, 2024 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden Via Licensing Alliance LLC Delaware DI Holding BV Netherlands |
|
| November 19, 2024 |
Dolby Laboratories, Inc. Insider Trading Policy -1- DOLBY LABORATORIES, INC. INSIDER TRADING POLICY I. PURPOSE Dolby Laboratories, Inc. and its subsidiaries (Dolby) prohibit trading securities of Dolby and other companies based on material, nonpublic information. Information is material if a reasonable investor would consider it important in making an investment decision. Material information may include: • Financial results and projections • N |
|
| November 19, 2024 |
Entry into a Material Definitive Agreement, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| November 19, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 27, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 19, 2024 |
Rule 10b5-1 Trading Plan Policy This policy formalizes required provisions for the contents of any Rule 10b5-1 trading plan relating to stock of Dolby Laboratories, Inc. |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| November 15, 2024 |
EXHIBIT 99.1 2025 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (“Executives”). Bonus Amounts: The amount each Executive may be eligible to receive under the 2025 Executive Bonus Plan (the “Executive Plan”) will be determined as summarized below and pursuant |
|
| November 13, 2024 |
DLB / Dolby Laboratories, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090889-10sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* DOLBY LABORATORIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) September |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2024 |
Dolby Laboratories Reports Third Quarter 2024 Financial Results Exhibit 99.1 Dolby Laboratories Reports Third Quarter 2024 Financial Results SAN FRANCISCO, August 7, 2024 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the third quarter of fiscal 2024. “Our third quarter results were in line with expectations,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “This quarter we continued to build momentum for th |
|
| August 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| August 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2024 |
EX-99.1 Exhibit 99.1 Dolby Laboratories Announces Agreement to Acquire GE Licensing from GE Aerospace Acquisition to strengthen Dolby’s licensing businesses and create opportunity for future growth SAN FRANCISCO, JUNE 6, 2024 – Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, announced today that it has entered into a definitive agreement to acquire GE Licensi |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission F |
|
| May 30, 2024 |
Exhibit 1.01 GLOSSARY OF TERMS The following table summarizes certain terms and abbreviations that may be used within the text of this report: Abbreviation Term CMRT RMI’s Conflict Minerals Reporting Template Communication Suspended - Not Interested RMI assigned smelter or refiner status for a facility which has strongly communicated a lack of interest in participation in the RMI RMAP program Conf |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal exec |
|
| May 2, 2024 |
Dolby Laboratories Reports Second Quarter 2024 Financial Results Exhibit 99.1 Dolby Laboratories Reports Second Quarter 2024 Financial Results SAN FRANCISCO, May 2, 2024 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the second quarter of fiscal 2024. “Our second quarter results were in line with our expectations,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “Dolby Atmos and Dolby Vision content is expand |
|
| May 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| May 2, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 11, 2024 |
March 11, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N. |
|
| February 13, 2024 |
DLB / Dolby Laboratories, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086862-17sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* DOLBY LABORATORIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) December |
|
| February 13, 2024 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0773-dolbylaboratoriesincc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Dolby Laboratories, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropri |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 9, 2024 |
Dolby Laboratories, Inc. Amended and Restated Bylaws (as amended on February 6, 2024) Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF DOLBY LABORATORIES, INC. (amended and restated on February 10, 2009) (amended on February 6, 2024) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF STOCKHOLDERS’ MEETINGS 1 2.5 [RESERVED |
|
| February 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 29, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| February 1, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 1, 2024 |
Dolby Laboratories Reports First Quarter 2024 Financial Results Exhibit 99.1 Dolby Laboratories Reports First Quarter 2024 Financial Results SAN FRANCISCO, February 1, 2024 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the first quarter of fiscal 2024. “Our first quarter results were in line with our expectations,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “We continue to bring new Dolby experiences t |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 17, 2023 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 29, 2023 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 29, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 16, 2023 |
Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2023 Financial Results Exhibit 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2023 Financial Results SAN FRANCISCO, November 16, 2023 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the fourth quarter and full year of fiscal 2023. “We finished our fiscal year on a solid note,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “We remain confident in our o |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| November 16, 2023 |
EXHIBIT 99.2 2024 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (“Executives”). Bonus Amounts: The amount each Executive may be eligible to receive under the 2024 Executive Bonus Plan (the “Executive Plan”) will be determined as summarized below and pursuant |
|
| August 3, 2023 |
Form of Amended and Restated Bylaws exhibit31-formofamendeda Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF DOLBY LABORATORIES, INC. (amended and restated on February 10, 2009) (amended on August 2, 2023) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF STOCKHOLDERS’ M |
|
| August 3, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| August 3, 2023 |
Dolby Laboratories Reports Third Quarter Fiscal 2023 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2023 Financial Results SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2023. "We continue to transform the way people enjoy their content," said Kevin Yeaman, President and CEO, Dolby Laboratories. "We remain focused on gro |
|
| May 24, 2023 |
EX-1.01 Exhibit 1.01 GLOSSARY OF TERMS The following table summarizes certain terms and abbreviations that may be used within the text of this report: Abbreviation Term CMRT RMI’s Conflict Minerals Reporting Template Communication Suspended - Not Interested RMI assigned smelter or refiner status for a facility which has strongly communicated a lack of interest in participation in the RMI RMAP prog |
|
| May 24, 2023 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal e |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| May 4, 2023 |
Dolby Laboratories Reports Second Quarter Fiscal 2023 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2023 Financial Results SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the second quarter of fiscal 2023. "In the first half of the year, we continued to bring Dolby Atmos and Dolby Vision to more consumers across our movies and TV, music and user-gen |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 10, 2023 |
DLB / Dolby Laboratories Inc - Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Dolby Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: February 28, 2023 Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| March 3, 2023 |
Power of Attorney (contained on signature page hereto) S-8 1 d468242ds8.htm S-8 As filed with the Securities and Exchange Commission on March 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DOLBY LABORATORIES, INC. (Exact name of Registrant as specified in its charter) Delaware 90-0199783 (State or other jurisdiction of incorporation |
|
| March 3, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Dolby Laboratories, Inc. |
|
| February 14, 2023 |
SC 13G 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* DOLBY LABORATORIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 10, 2023 |
DLB / Dolby Laboratories, Inc. / Clearbridge Investments, LLC Passive Investment dolb22a13.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 25659T107 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* DOLBY LABORATORIES, INC. (Name of Issuer) Class A common stock, $0.001 par value (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2022 (Dat |
|
| February 10, 2023 |
2020 Stock Plan, as amended and restated on February 7, 2023 (“2020 Stock Plan") Exhibit 10.1 Adopted Effective February 16, 2005 Amended and Restated February 14, 2006 Amended and Restated June 6, 2006 Amended and Restated February 6, 2007 Amended and Restated November 6, 2007 Amended and Restated November 9, 2010 Amended and Restated February 2, 2011 Amended and Restated July 26, 2011 Amended and Restated February 5, 2013 Amended and Restated September 24, 2013 Amended and R |
|
| February 10, 2023 |
Dolby Laboratories, Inc. Employee Stock Purchase Plan (as amended and restated on February 7, 2023) Exhibit 10.2 DOLBY LABORATORIES, INC. EMPLOYEE STOCK PURCHASE PLAN Adopted Effective February 16, 2005 Amended and Restated on October 13, 2005 Amended and Restated on February 5, 2008 Amended and Restated on November 4, 2008; Effective May 18, 2009 Amended and Restated on November 7, 2011; Effective May 15, 2012 Amended and Restated on September 25, 2012; Effective November 15, 2012 Amended and R |
|
| February 9, 2023 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Dolby Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 2, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 2, 2023 |
Dolby Laboratories Reports First Quarter 2023 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports First Quarter 2023 Financial Results SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2023. "We are bringing an increasing number of Dolby experiences to more people around the world and demand for immersive experiences continues to be strong," |
|
| February 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| December 19, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| November 18, 2022 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 53)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| November 18, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 18, 2022 |
EXHIBIT 99.1 2023 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (?Executives?). Bonus Amounts: The amount each Executive may be eligible to receive under the 2023 Executive Bonus Plan (the ?Executive Plan?) will be determined as summarized below and pursuant |
|
| November 18, 2022 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 30, 2022 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 18, 2022 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| November 17, 2022 |
Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the fourth quarter and full year of fiscal 2022. "We continue to make progress in bringing the Dolby experience to all the ways people enjoy their content," said Kevin Ye |
|
| November 17, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 9, 2022 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Dolby Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: August 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| August 9, 2022 |
Dolby Laboratories Reports Third Quarter Fiscal 2022 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2022 Financial Results SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2022. For the third quarter, Dolby reported total revenue of $289.6 million, compared to $286.8 million for the third quarter of fiscal 2021. "While the |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended July 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLB |
|
| August 9, 2022 |
Offer Letter dated April 6, 2022 by and between Shriram Revankar and Dolby Laboratories, Inc. April 6, 2022 Shriram Revankar Dear Shriram, as Senior Vice President, Advanced Technology Group, reporting to Kevin Yeaman, President & Chief Executive Officer. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 26, 2022 |
Exhibit 1.01 GLOSSARY OF TERMS The following table summarizes certain terms and abbreviations that may be used within the text of this report: Abbreviation Term CMRT RMI?s Conflict Minerals Reporting Template Communication Suspended - Not Interested RMI assigned smelter or refiner status for a facility which has strongly communicated a lack of interest in participation in the RMI RMAP program Conf |
|
| May 26, 2022 |
SD 1 d345800dsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Ad |
|
| May 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended April 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| May 5, 2022 |
Dolby Laboratories Reports Second Quarter Fiscal 2022 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2022 Financial Results SAN FRANCISCO, May 05, 2022 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the second quarter of fiscal 2022. For the second quarter, Dolby reported total revenue of $334.4 million, compared to $319.6 million for the second quarter of fiscal 2021. "We fee |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 11, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 9, 2022 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0750-dolbylaboratoriesincc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Dolby Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriat |
|
| February 8, 2022 |
DLB / Dolby Laboratories, Inc. / Clearbridge Investments, LLC Passive Investment CUSIP NO. 25659T107 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 12)* DOLBY LABORATORIES, INC. (Name of Issuer) Class A common stock, $0.001 par value (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 4, 2022 |
Offer Letter dated September 23, 2021 by and between Robert Park and Dolby Laboratories, Inc. September 23, 2021 Robert Park [Address Redacted] [Address Redacted] Dear Robert, It is my distinct pleasure to confirm to you our offer to join Dolby Laboratories, Inc. |
|
| February 4, 2022 |
Letter Agreement dated October 15, 2021 by and between Lewis Chew and Dolby Laboratories, Inc. October 15, 2021 Mr. Lewis Chew [Address Redacted] [Address Redacted] Re: Retirement and Transition Dear Lewis: This letter will confirm the terms of your retirement from your position as Chief Financial Officer (?CFO?) of Dolby Laboratories, Inc. (the ?Company?). The Company?s Board of Directors (the ?Board?) and the Company?s other executives thank you for your years of service to the Company an |
|
| February 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| February 3, 2022 |
Dolby Laboratories Reports First Quarter Fiscal 2022 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports First Quarter Fiscal 2022 Financial Results SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2022. For the first quarter, Dolby reported total revenue of $351.6 million, compared to $389.9 million for the first quarter of fiscal 2021. "We made g |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 17, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| December 8, 2021 |
Dolby Appoints Tony Prophet to its Board of Directors EXHIBIT 99.1 Dolby Appoints Tony Prophet to its Board of Directors SAN FRANCISCO, December 8, 2021 ? Dolby Laboratories, Inc. (NYSE:DLB) announced today the appointment of Tony Prophet to its Board of Directors, effective December 6, 2021. Over the course of many years, Tony has established himself as a technology industry leader who has helped guide companies across multiple disciplines. Most rec |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| November 30, 2021 |
EX-99.1 2 d134641dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersign |
|
| November 30, 2021 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 52)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street San Fran |
|
| November 17, 2021 |
Offer Letter dated February 11, 2010 by and between Giles Baker and Dolby Laboratories, Inc. |
|
| November 17, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 24, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 17, 2021 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 24, 2021 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 17, 2021 |
2020 Stock Plan, as amended and restated on July 26, 2021 (“2020 Stock Plan") Exhibit 10.3 Adopted Effective February 16, 2005 Amended and Restated February 14, 2006 Amended and Restated June 6, 2006 Amended and Restated February 6, 2007 Amended and Restated November 6, 2007 Amended and Restated November 9, 2010 Amended and Restated February 2, 2011 Amended and Restated July 26, 2011 Amended and Restated February 5, 2013 Amended and Restated September 24, 2013 Amended and R |
|
| November 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 16, 2021 |
Dolby Laboratories Reports Fourth Quarter and Fiscal 2021 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal 2021 Financial Results SAN FRANCISCO, Nov. 16, 2021 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the fourth quarter and fiscal year that ended September 24, 2021. For the fourth quarter, Dolby reported total revenue of $285.0 million, compared to $271.2 million for the fo |
|
| November 12, 2021 |
EXHIBIT 99.1 2022 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (?Executives?). Bonus Amounts: The amount each Executive may be eligible to receive under the 2022 Executive Bonus Plan (the ?Executive Plan?) will be determined as summarized below and pursuant |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| October 15, 2021 |
Exhibit 99.1 Robert Park Joins Dolby Laboratories as Chief Financial Officer Seasoned Executive Brings Decades of Financial and Business Leadership to Dolby SAN FRANCISCO ? October 15, 2021 ? Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, today announced the appointment of Robert Park, a global finance leader with a track record of guiding companies through g |
|
| July 29, 2021 |
Dolby Laboratories Reports Third Quarter Fiscal 2021 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2021 Financial Results SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2021. For the third quarter, Dolby reported total revenue of $286.8 million, compared to $246.9 million for the third |
|
| July 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 25, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| July 29, 2021 |
Form of Restricted Stock Unit Agreement - France DOLBY LABORATORIES, INC. 2020 STOCK PLAN NOTICE OF GRANT OF RESTRICTED STOCK UNITS FOR PARTICIPANTS IN FRANCE Unless otherwise defined herein, the terms defined in the Dolby Laboratories, Inc. 2020 Stock Plan, as amended from time to time (the ?U.S. Plan?), the Dolby Laboratories, Inc. 2020 Stock Plan French Sub-Plan for Restricted Stock Units and Performance Stock Units (the ?French Sub-Plan? and |
|
| July 29, 2021 |
French Sub-Plan to the 2020 Stock Plan Dolby Laboratories, Inc. 2020 Stock Plan French Sub-Plan for Restricted Stock Units and Performance Stock Units (?Sub-Plan?) The Dolby Laboratories, Inc. (?Dolby? or ?the Company?) 2020 Stock Plan (the ?Plan?) was approved by the Company's stockholders on February 4, 2020 for the benefit of Employees and Directors of the Company and/or any Related Entity, including any Related Entities in France, |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2021 |
Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2020 Exhibit 1.01 Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2020 Introduction This Conflict Minerals Report (this ?Report?) of Dolby Laboratories, Inc. (?Dolby? or the ?Company?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2020 to |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal exec |
|
| May 4, 2021 |
Dolby Laboratories Reports Second Quarter Fiscal 2021 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2021 Financial Results SAN FRANCISCO, May 04, 2021 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the second quarter of fiscal 2021. For the second quarter, Dolby reported total revenue of $319.6 million, compared to $351.8 million for the second quarter of fiscal 2020. "We con |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 26, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2021 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2021 |
EXHIBIT 99.2 Dolby Laboratories Announces Executive Retirement Executive Vice President and Chief Financial Officer, Lewis Chew to retire later this year SAN FRANCISCO, May 04, 2021 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced that after more than a 30 year career of financial leadership, Lewis Chew, Executive Vice President and Chief Financial Officer has decided to reti |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2021 |
Dolby Appoints Emily Rollins to its Board of Directors EX-99.1 Exhibit 99.1 Dolby Appoints Emily Rollins to its Board of Directors SAN FRANCISCO, February 25, 2021 – Dolby Laboratories, Inc. (NYSE:DLB) announced today the appointment of Emily Rollins to its Board of Directors and to the Audit Committee of the Board, effective February 24, 2021. Throughout her career at Deloitte & Touche LLP, Ms. Rollins served in various positions since 1992, includin |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Dolby Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2021 |
CUSIP NO. 25659T107 13G Page 1 of 7 dolb20a11.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 25659T107 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* DOLBY LABORATORIES, INC. (Name of Issuer) Class A common stock, $0.001 par value (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2020 (Dat |
|
| February 5, 2021 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| January 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 25, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 28, 2021 |
Dolby Laboratories Reports First Quarter Fiscal 2021 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports First Quarter Fiscal 2021 Financial Results SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the first quarter of fiscal 2021. For the first quarter, Dolby reported total revenue of $389.9 million, compared to $291.9 million for the first |
|
| December 18, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 18, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| November 20, 2020 |
EX-99.14 3 d17236dex9914.htm EX-99.14 Exhibit 14 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Patrick McCabe, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D |
|
| November 20, 2020 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 51)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| November 20, 2020 |
EX-99.1 2 d17236dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigne |
|
| November 16, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 25, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 16, 2020 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 25, 2020 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 13, 2020 |
EX-99.1 2 d48032dex991.htm EX-99.1 EXHIBIT 99.1 2021 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (“Executives”). Bonus Amounts: The amount each Executive may be eligible to receive under the 2021 Executive Bonus Plan (the “Executive Plan”) will be determin |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2020 |
Dolby Laboratories Reports Fourth Quarter and Fiscal 2020 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal 2020 Financial Results SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the fourth quarter and fiscal year that ended September 25, 2020. For the fourth quarter, Dolby reported total revenue of $271.2 million, compared to $298.8 million for the fo |
|
| September 28, 2020 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 50)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| August 3, 2020 |
Dolby Laboratories Reports Third Quarter Fiscal 2020 Financial Results EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2020 Financial Results SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2020. For the third quarter, Dolby reported total revenue of $246.9 million, compared to $302.2 million for the third |
|
| May 28, 2020 |
Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2019 EX-1.01 2 d935681dex101.htm EX-1.01 Exhibit 1.01 GLOSSARY OF TERMS The following table summarizes certain terms and abbreviations that may be used within the text of this report: Abbreviation Term CMRT RMI’s Conflict Minerals Reporting Template Communication Suspended—Not Interested RMI assigned smelter or refiner status for a facility which has strongly communicated a lack of interest in particip |
|
| May 28, 2020 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal e |
|
| May 4, 2020 |
Dolby Laboratories Reports Second Quarter Fiscal 2020 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2020 Financial Results SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the second quarter of fiscal 2020. For the second quarter, Dolby reported total revenue of $351.8 million, compared to $338.3 million for the sec |
|
| May 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 27, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| March 19, 2020 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| March 19, 2020 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 49)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| March 19, 2020 |
EX-99.14 Exhibit 14 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the·-undersigned statements on Schedule 13D or Schedule 13G, and Forms ID, 3,4 and 5, in |
|
| February 25, 2020 |
As filed with the Securities and Exchange Commission on February 25, 2020 As filed with the Securities and Exchange Commission on February 25, 2020 Registration No. |
|
| February 14, 2020 |
DLB / Dolby Laboratories, Inc. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Dolby Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2020 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Dolby Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| February 7, 2020 |
Dolby Laboratories, Inc. 2020 Stock Plan (formerly known as the 2005 Stock Plan) EX-10.1 2 d902514dex101.htm EX-10.1 Exhibit 10.1 Adopted Effective February 16, 2005 Amended and Restated February 14, 2006 Amended and Restated June 6, 2006 Amended and Restated February 6, 2007 Amended and Restated November 6, 2007 Amended and Restated November 9, 2010 Amended and Restated February 2, 2011 Amended and Restated July 26, 2011 Amended and Restated February 5, 2013 Amended and Resta |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorpor |
|
| January 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 29, 2020 |
Quarterly Report - 10-Q - FISCAL Q1 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 27, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| January 29, 2020 |
Form of Executive Performance-Based Restricted Stock Units DOLBY LABORATORIES, INC. 2005 STOCK PLAN NOTICE OF GRANT OF EXECUTIVE PERFORMANCE-BASED RESTRICTED STOCK UNITS Unless otherwise defined herein, the terms defined in the Dolby Laboratories, Inc. 2005 Stock Plan, as amended from time to time (the “Plan”) shall have the same defined meanings in this Notice of Grant of Executive Performance-Based Restricted Stock Units (the “Notice of Grant”) and the |
|
| January 29, 2020 |
Dolby Laboratories Reports First Quarter Fiscal 2020 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports First Quarter Fiscal 2020 Financial Results SAN FRANCISCO, Jan. 29, 2020 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the first quarter of fiscal 2020. For the first quarter, Dolby reported total revenue of $291.9 million, compared to $302.4 million for the first |
|
| December 18, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 18, 2019 |
DLB / Dolby Laboratories, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| November 25, 2019 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 27, 2019 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 25, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 27, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 25, 2019 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Dolby Laboratories, Inc. (“us,” “our,” “we” or the “Company”) is a summary of the rights of our common stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws currently in effect. This summary does not purport to be complete and is qualified in it |
|
| November 18, 2019 |
EX-99.1 Exhibit 99.1 2020 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (“Executives”). Bonus Amounts: The amount each Executive may be eligible to receive under the 2020 Executive Bonus Plan (the “Executive Plan”) will be determined as summarized below and |
|
| November 18, 2019 |
EX-99.2 Exhibit 99.2 DOLBY LABORATORIES, INC. 2005 STOCK PLAN NOTICE OF GRANT OF EXECUTIVE PERFORMANCE-BASED RESTRICTED STOCK UNITS Unless otherwise defined herein, the terms defined in the Dolby Laboratories, Inc. 2005 Stock Plan, as amended from time to time (the “Plan”) shall have the same defined meanings in this Notice of Grant of Executive Performance-Based Restricted Stock Units (the “Notic |
|
| November 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2019 |
Dolby Laboratories Reports Fourth Quarter and Fiscal 2019 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal 2019 Financial Results SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the fourth quarter and fiscal year that ended September 27, 2019. For the fourth quarter, Dolby reported total revenue of $298.8 million, co |
|
| September 24, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 48)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| August 2, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| August 1, 2019 |
Dolby Laboratories Reports Third Quarter Fiscal 2019 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2019 Financial Results SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the third quarter (Q3) of fiscal 2019. For the third quarter, Dolby reported total revenue of $302.2 million, compared to $214.8 million for the third quarter of fiscal 2018. “We c |
|
| August 1, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 Dolby Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 24, 2019 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| July 24, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 47)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| July 24, 2019 |
EX-99.13 Exhibit 13 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D or Schedule 13G, and Forms ID, 3,4 and 5, in |
|
| July 3, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 46)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| May 30, 2019 |
Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2018 EX-1.01 Exhibit 1.01 Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2018 Introduction This Conflict Minerals Report (this “Report”) of Dolby Laboratories, Inc. (“Dolby” or the “Company”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, |
|
| May 30, 2019 |
DLB / Dolby Laboratories, Inc. SD - - SD SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal e |
|
| May 14, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commissi |
|
| May 14, 2019 |
EX-99.1 2 d648318dex991.htm EX-99.1 Exhibit 99.1 Dolby Appoints Anjali Sud to its Board of Directors New director brings extensive knowledge of the technology industry and operational experience to the boardroom SAN FRANCISCO, May 14, 2019 – Dolby Laboratories, Inc. (NYSE:DLB) announced today the appointment of Anjali Sud to its Board of Directors as a new independent director, effective May 13, 2 |
|
| May 8, 2019 |
Quarterly Report - 10-Q: FISCAL Q2 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 29, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| May 7, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 45)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| May 1, 2019 |
Dolby Laboratories Reports Second Quarter Fiscal 2019 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2019 Financial Results SAN FRANCISCO, May 01, 2019 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the second quarter (Q2) of fiscal 2019. For the second quarter, Dolby reported total revenue of $338.3 million, compared to $299.7 million for th |
|
| May 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 1, 2019 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 1, 2019 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 28, 2018 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| April 1, 2019 |
Annual Report - 10-K/A FY 2018 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (AMENDMENT No. 1) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 28, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Numb |
|
| March 13, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 44)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| February 21, 2019 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 43)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| February 14, 2019 |
DLB / Dolby Laboratories, Inc. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* Dolby Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 11, 2019 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC Passive Investment dolbylaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: Dolby Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropri |
|
| February 8, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2019 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Comm |
|
| February 1, 2019 |
Quarterly Report - 10-Q-Q1FY2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 28, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| January 30, 2019 |
Dolby Laboratories Reports First Quarter Fiscal 2019 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports First Quarter Fiscal 2019 Financial Results SAN FRANCISCO, Jan. 30, 2019 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the first quarter (Q1) of fiscal 2019. For the first quarter, Dolby reported total revenue of $302.4 million, compared to $299.5 million for the |
|
| January 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 30, 2019 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 19, 2018 |
DLB / Dolby Laboratories, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| December 19, 2018 |
DLB / Dolby Laboratories, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 30, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 42)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| November 16, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2018 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Com |
|
| November 16, 2018 |
2019 DOLBY EXECUTIVE BONUS PLAN EX-99.1 2 d652080dex991.htm EX-99.1 Exhibit 99.1 2019 DOLBY EXECUTIVE BONUS PLAN Eligibility: Eligible employees are the executive officers and other officers of the Company and its subsidiaries who are selected by the Compensation Committee (“Executives”). Bonus Amounts: The amount each Executive may be eligible to receive under the 2019 Executive Bonus Plan (the “Executive Plan”) will be determi |
|
| November 15, 2018 |
DLB / Dolby Laboratories, Inc. 10-K: FY'18 Q4 (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 28, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOLBY |
|
| November 15, 2018 |
List of significant subsidiaries of the Registrant Exhibit 21.1 SIGNIFICANT SUBSIDIARIES OF DOLBY LABORATORIES, INC. As of September 28, 2018 Name Jurisdiction of Incorporation/Organization Dolby Laboratories, Inc. California Dolby Laboratories Licensing Corporation New York Dolby International AB Sweden |
|
| November 2, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) |
|
| October 24, 2018 |
Dolby Laboratories Reports Fourth Quarter and Fiscal 2018 Financial Results EXHIBIT 99.1 Dolby Laboratories Reports Fourth Quarter and Fiscal 2018 Financial Results SAN FRANCISCO, Oct. 24, 2018 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the fourth quarter (Q4) and fiscal year that ended September 28, 2018. For the fourth quarter, Dolby reported total revenue of $265.3 million, compared to $242.0 million for t |
|
| October 24, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 24, 2018 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2018 |
Offer Letter dated June 26, 2018 by and between Todd Pendleton and Dolby Laboratories, Inc. exhibit101offerlettertot Exhibit 10.1 June 26th, 2018 Todd Pendleton 4711 Balboa Ave Encino, CA 91316 Dear Todd, It is my distinct pleasure to confirm to you our offer to join Dolby Laboratories, Inc. (“Dolby”) as Chief Marketing Officer, reporting to Kevin Yeaman, President & Chief Executive Officer. We will assume your date of hire to be Monday, July 9th, 2018. Your starting base salary will be |
|
| August 1, 2018 |
DLB / Dolby Laboratories, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 29, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DOL |
|
| July 25, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 25, 2018 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 25, 2018 |
Dolby Laboratories Reports Third Quarter Fiscal 2018 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Third Quarter Fiscal 2018 Financial Results SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the third quarter (Q3) of fiscal 2018. For the third quarter, Dolby reported total revenue of $317.4 million, compared to $305.7 million for the |
|
| July 5, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 41)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| June 29, 2018 |
EX-99.1 2 d864662dex991.htm EX-99.1 Exhibit 99.1 Statement by Dolby Laboratories, Inc.’s Board of Directors Regarding the Passing of Nicholas Donatiello, Jr. SAN FRANCISCO, June 29, 2018 – (NYSE: DLB) – It is with deep sadness that we announce the passing of Nicholas Donatiello, Jr., our fellow Board member at Dolby Laboratories, Inc. Nick was an industry leader and close friend who will be greatl |
|
| June 29, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2018 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commiss |
|
| June 21, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 40)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| June 21, 2018 |
EX-99.12 3 d534436dex9912.htm EX-99.12 Exhibit 12 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Sundance Banks, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D |
|
| June 21, 2018 |
EX-99.1 2 d534436dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersign |
|
| June 6, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 39)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| May 24, 2018 |
Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2017 EX-1.01 Exhibit 1.01 Dolby Laboratories, Inc. Conflict Minerals Report For Calendar Year Ended December 31, 2017 Introduction This Conflict Minerals Report (this “Report”) of Dolby Laboratories, Inc. (“Dolby” or the “Company”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, |
|
| May 24, 2018 |
DLB / Dolby Laboratories, Inc. SD SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1275 Market Street San Francisco, CA 94103-1410 (Address of principal e |
|
| May 23, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 38)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| May 11, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 37)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| May 2, 2018 |
DLB / Dolby Laboratories, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 DO |
|
| April 25, 2018 |
EX-99.1 2 d575982dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersign |
|
| April 25, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 36)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| April 24, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 24, 2018 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 24, 2018 |
Dolby Laboratories Reports Second Quarter Fiscal 2018 Financial Results EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Dolby Laboratories Reports Second Quarter Fiscal 2018 Financial Results SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) - Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the second quarter (Q2) of fiscal 2018. For the second quarter, Dolby reported total revenue of $301.4 million, compared to $267.5 million for |
|
| March 29, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 35)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| March 29, 2018 |
EX-99.10 3 d561559dex9910.htm EX-99.10 Exhibit 10 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Sundance Banks, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D |
|
| March 29, 2018 |
EX-99.1 2 d561559dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersign |
|
| March 14, 2018 |
DLB / Dolby Laboratories, Inc. CORRESP March 14, 2018 Via EDGAR Ms. Cecilia Blye, Chief Office of Global Security Risk Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Dolby Laboratories, Inc. Form 10-K for the Fiscal Year Ended September 29, 2017 Filed on November 16, 2017 File No. 001-32431 Dear Ms. Blye: On behalf of Dolby Laboratories, Inc. (the “Company”), we respectfully submit this letter in response |
|
| March 1, 2018 |
EX-99.12 Exhibit 12 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Andy Sherman, Daniel Rodriguez, Sundance Banks, Morrison & Foerster LLP and Shartsis Friese LLP, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned statements on Schedule 13D or Schedule 13G, and Forms ID |
|
| March 1, 2018 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each sha |
|
| March 1, 2018 |
DLB / Dolby Laboratories, Inc. / Dolby Dagmar - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 34)* DOLBY LABORATORIES, INC. (Name of Issuer) CLASS A COMMON STOCK CLASS B COMMON STOCK (Title of Class of Securities) CLASS A COMMON STOCK: 25659T107 CLASS B COMMON STOCK: Not Applicable (CUSIP Number) Dolby Laboratories, Inc. 1275 Market Street S |
|
| February 28, 2018 |
DLB / Dolby Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2018 |
DLB / Dolby Laboratories, Inc. / Clearbridge Investments, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* Dolby Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25659T107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 9, 2018 |
DLB / Dolby Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2018 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32431 90-0199783 (State or other jurisdiction of incorporation) (Comm |
|
| February 9, 2018 |
DLB / Dolby Laboratories, Inc. / VANGUARD GROUP INC Passive Investment dolbylaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Dolby Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 25659T107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropri |
|
| January 31, 2018 |
DLB / Dolby Laboratories, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 29, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From To Commission File Number: 001-32431 |
|
| January 24, 2018 |
DLB / Dolby Laboratories, Inc. FORM 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 24, 2018 DOLBY LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-32431 90-0199783 (State or Other Jurisdiction of Incorporation) (Commission F |
